Kyle Contini, MD
Family Medicine · Vernon, FLNPI 1336400266
Payments from drug & device makers
Across 153 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$566
- AbbVie$555
- Amgen$228
- GSK$184
- Astellas Pharma US Inc$184
- Lilly USA, LLC$170
- plus $871 from 19 others
What the payments were for
- Consulting fees$1756%
- Food & beverage$2,48890%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $566 |
| AbbVie(2 entities) | 41 | $555 |
| Amgen | 7 | $228 |
| GSK | 12 | $184 |
| Astellas Pharma US Inc | 5 | $184 |
| Lilly USA, LLC | 12 | $170 |
| Phathom Pharmaceuticals, Inc. | 4 | $166 |
| Novo Nordisk | 5 | $105 |
| Bayer | 4 | $83 |
| Novartis | 6 | $79 |
| Johnson & Johnson | 3 | $75 |
| Nevro Corp. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Esperion Therapeutics, Inc. | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Eisai Inc. | 2 | $26 |
| Vertex | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Exact Sciences | 1 | $14 |
| Scynexis, Inc. | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,758 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 62 | $94,440 |
| EliquisApixaban | 71 | $91,358 |
| FarxigaDapagliflozin Propanediol | 82 | $82,908 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $65,443 |
| XareltoRivaroxaban | 46 | $55,176 |
| JardianceEmpagliflozin | 36 | $33,717 |
| EntrestoSacubitril/Valsartan | 23 | $26,042 |
| OzempicSemaglutide | 12 | $23,069 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $23,001 |
| TrulicityDulaglutide | 14 | $19,574 |
| JanuviaSitagliptin Phosphate | 20 | $18,302 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 336 | $9,043 |
| MyrbetriqMirabegron | 14 | $8,641 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $8,635 |
| DayvigoLemborexant | 12 | $4,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $170 | $114,01476 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $566 | $105,909106 claims |
| GSKTrelegy Ellipta | $184 | $65,44353 claims |
| Johnson & JohnsonXarelto | $75 | $55,17646 claims |
| NovartisEntresto | $79 | $26,04223 claims |
| Novo NordiskOzempic | $105 | $23,06912 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $8,64114 claims |
| Eisai Inc.Dayvigo | $26 | $4,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Vernon
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.